EVO+ Visian ICL receives CE mark
The EVO+ Visian ICL with aspheric optic has received a CE mark for commercialization in the European Union, according to a STAAR Surgical press release.
Indicated for the correction or reduction of hyperopia and myopia between +3 D and –18 D, the EVO+ Visian ICL with aspheric (EDOF) optic is surgically implanted between the iris and the natural lens.
The company plans to introduce the lens to a group of surgeons for early effectiveness observational use, eliciting feedback from surgeons on the performance of the lens, patient acceptance and practice development, Caren Mason, STAAR Surgical president and CEO, said in the release.
“This represents an important new treatment option for eligible patients between 21 and 45 years of age living with nearsightedness or farsightedness,” she added.